23andMe Holding Co. (NASDAQ:ME) Q2 2024 Earnings Conference Call November 8, 2023 4:30 PM ET

Company Participants

Ian Cooney - Senior Director, IR

Anne Wojcicki - Chief Executive Officer and Co-Founder

Joseph Selsavage - Interim Chief Financial and Accounting Officer

Jennifer Low - Head of Therapeutics

Bill Richards - Head of Therapeutics Discovery

Conference Call Participants

Chad Wiatrowski - TD Cowen

David Lebowitz - Citigroup Inc.

Operator

Hello, and welcome to 23andMe's Fiscal Year 2024 Second Quarter Financial Results Conference Call. As a reminder, this call is being recorded. [Operator Instructions]

I would now like to turn the call over to Ian Cooney, Senior Director of Investor Relations at 23andMe to lead off the call. Thank you. Please go ahead.

Ian Cooney

Thank you. Before we begin, I encourage everyone to go to investors.23andme.com to find the press release we issued earlier today reporting our financial results for the second quarter. A replay of today's webcast will also be available on our website. Please note that certain statements made during this call regarding matters that are not historical facts, including, but not limited to, management's outlook or predictions for future periods are forward-looking statements. These statements are based solely on information that is now available to us. We encourage you to review the section entitled Forward-Looking Statements in our press release, which applies to this call. Also, please refer to our SEC filings, which can be found on our website and the SEC's website for a discussion of numerous factors that may impact our future performance. We also discuss certain non-GAAP measures important information on our use of these measures and reconciliation to U.S. GAAP may be found in our earnings release.

Joining us on our call today are Anne Wojcicki, our Chief Executive Officer and Co-Founder; and Joe Selsavage, our Interim Chief Financial and Accounting Officer; Bill Richards, our Head of Therapeutics Discovery; and Jennifer Low, our Head of Therapeutics Development will join us for Q&A.

I'd now like to turn the call over to Anne.

Anne Wojcicki

Thank you, Ian. To kick off the call, I would like to start with an update on our strategy. 23andMe's mission has always been to help people access, understand and benefit from the human genome. The 23andMe brand is most known for how we transformed access to genetic information and enabled over 14 million people to learn about themselves, their ancestry and their health risks.